AstraZeneca in oncology partnerships with University of Cambridge, Cancer Research UK and Blackfield

9 July 2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has reached agreement with the University of Cambridge and Cancer Research UK for a two-year collaboration on three preclinical and clinical oncology projects. The accord aims to advance cancer research through the study of tumor mutations and new investigational therapies in prostate, pancreatic and potentially other cancers.

As part of a major overhaul of its R&D sites, AstraZeneca recently announced that by 2016 its new UK-based global R&D center and corporate headquarters will be located at the Cambridge Biomedical Campus ( The Pharma Letter March 19).

This latest alliance will bring together scientists from AstraZeneca’s small molecule and MedImmune’s biologics units and researchers across the region from the university, affiliated institutes and the UK’s National Health Service (NHS), all of which are members of the Cambridge Cancer Center. The three projects involve:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK